SCHEMBL5218205

SCHEMBL5218205

CC(C)(C)c1cccc(-n2cc(-c3nc4ccccc4o3)cn2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 4/20 0.44
▸ TP53 P04637 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ KDM4E B2RXH2 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ HPGD P15428 3/20 0.44
▸ P2RY6 Q15077 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ MET P08581 1/20 0.41
▸ NPC1 O15118 6/20 0.40
▸ RAB9A P51151 4/20 0.39
▸ GFER P55789 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ HCRTR1 O43613 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ STAT1 P42224 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5221023 0.89 EPHX2 (0.52) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL6174671 0.83 ALDH1A1 (0.50) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL5218826 0.80 P2RY14 (0.49) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL5219267 0.80 HSD17B10 (0.45) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL5220891 0.80 NPC1 (0.45) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL5224725 0.80 NPC1 (0.47) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL13327646 0.79 NPC1 (0.54) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL182360 0.79 HPSE (0.55) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL5219184 0.77 RAB9A (0.44) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2
SCHEMBL5217963 0.77 NPC1 (0.46) HSD17B10TP53KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 — — EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 — — EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 — — US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 — — EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 — — WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 — — WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 — — US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C HSD17B10 1908/4885TP53 4833/4885KMT2A 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback